The “GLP‐1 for bridging of hyperglycaemia during cardiac surgery” (GLOBE) study is a large randomised parallel placebo‐controlled trial, currently underway, with the intention of recruiting 274 patients undergoing cardiac surgery, with or without diabetes mellitus.84 Patients will receive 0.6‐mg liraglutide or placebo the evening before and 1.2‐mg liraglutide or placebo just prior to surgery. The gene discussed is GLP1R; the disease is diabetes mellitus.